SEC Company Response from Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Nov 30, 2011
Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Nov. 30, 2011 · CIK: 0001279704 · Accession: 0001144204-11-067637
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-175284
Letter
Re:
Unassociated Document
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
November 30, 2011
Novelos Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-175284)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act”) the undersigned, as underwriter, joins with the request of Novelos Therapeutics, Inc. that the effective date of the above-captioned Registration Statement be accelerated so that the same will become effective at 4:30 p.m., Eastern time, on Wednesday, November 30, 2011, or as soon as practicable thereafter.
Pursuant to Rule 418(a)(7) and Rule 460 of the General Rules and Regulations under the Act, the undersigned advises that between October 4, 2011 and November 09, 2011, 207 copies of the Preliminary Prospectus, dated October 4, 2011 have been distributed as follows:
Sent to Underwriters: 0
Sent to Dealers: 0
Sent to Institutional Investors: 207
Sent to Others: 0
Total: 207
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
RODMAN & RENSHAW, LLC
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
November 30, 2011
Re:
Novelos Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-175284)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act”) the undersigned, as underwriter, joins with the request of Novelos Therapeutics, Inc. that the effective date of the above-captioned Registration Statement be accelerated so that the same will become effective at 4:30 p.m., Eastern time, on Wednesday, November 30, 2011, or as soon as practicable thereafter.
Pursuant to Rule 418(a)(7) and Rule 460 of the General Rules and Regulations under the Act, the undersigned advises that between October 4, 2011 and November 09, 2011, 207 copies of the Preliminary Prospectus, dated October 4, 2011 have been distributed as follows:
Sent to Underwriters: 0
Sent to Dealers: 0
Sent to Institutional Investors: 207
Sent to Others: 0
Total: 207
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
RODMAN & RENSHAW, LLC
By:
/s/ John Borer
Name: John Borer
Title: Head of Investment Banking
Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020
Tel: 212 356 0500 Fax: 212 581 5690 www.rodm.com Member: FINRA, SIPC